5-Aminosalicylic Acid Capsule Formulation

Patent No. EP2922532 (titled "5-Aminosalicylic Acid Capsule Formulation") was filed by Allergan Pharmaceuticals on Nov 19, 2013. The application was issued on Mar 6, 2019.

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

Company	Opposition Date	Representative
WIBBELMANN	Dec 5, 2019	WIBBELMANN

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

Date
Description

Get instant alerts for new documents

Oct 23, 2020
Communication to the parties concerning the termination of the opposition proceedings (opponent)
Oct 23, 2020
Communication to the parties concerning the termination of the opposition proceedings (proprietor)
Oct 20, 2020
Termination of the opposition proceedings with revocation of patent
Jul 16, 2020
(Electronic) Receipt
Jul 16, 2020
Advice of delivery
Jul 14, 2020
Advice of delivery
Jul 8, 2020
Acknowledgement of a document
Jul 8, 2020
Acknowledgement of a document
Jul 8, 2020
Brief communication - Opposition proceedings
Jul 8, 2020
Decision revoking the European patent
Jul 8, 2020
Decision revoking the European patent
Jul 3, 2020
(Electronic) Receipt
Jul 3, 2020
Letter accompanying subsequently filed items
Jul 3, 2020
Request for revocation of patent
Jun 24, 2020
Brief communication - Opposition proceedings
Jun 24, 2020
Brief communication in opposition procedure - time limit
Jun 18, 2020
(Electronic) Receipt
Jun 18, 2020
Letter accompanying subsequently filed items
Jun 18, 2020
Letter regarding the opposition procedure (no time limit)
May 8, 2020
Brief communication - Opposition proceedings
May 8, 2020
Grant of extension of time limit (opposition procedure)
Apr 22, 2020
(Electronic) Receipt
Apr 22, 2020
Letter regarding the opposition procedure (no time limit)
Apr 22, 2020
Request for extension of time limit
Dec 20, 2019
Communication of a notice of opposition and request to file observations
Dec 20, 2019
Notice of further oppositions to opponent(s)
Dec 11, 2019
Communication of a notice of opposition - first information to patent proprietor
Dec 6, 2019
Consolidated list of cited opposition documents
Dec 5, 2019
(Electronic) Receipt
Dec 5, 2019
Citation in opposition procedure - 001
Dec 5, 2019
Citation in opposition procedure - 002
Dec 5, 2019
Citation in opposition procedure - 003
Dec 5, 2019
Citation in opposition procedure - 004
Dec 5, 2019
Citation in opposition procedure - 005
Dec 5, 2019
Citation in opposition procedure - 006
Dec 5, 2019
Citation in opposition procedure - 007
Dec 5, 2019
Notice of opposition
Dec 5, 2019
Notice of opposition
Dec 5, 2019
Published international application - A1
Mar 18, 2019
Transmission of the certificate for a European patent pursuant to Rule 74 EPC
Feb 7, 2019
Decision to grant a European patent
Jan 23, 2019
(Electronic) Receipt
Jan 23, 2019
French translation of claims
Jan 23, 2019
German translation of the claims
Jan 23, 2019
Letter accompanying subsequently filed items
Sep 21, 2018
Bibliographic data of the European patent application
Sep 21, 2018
Communication about intention to grant a European patent
Sep 21, 2018
Intention to grant (signatures)
Sep 21, 2018
Text intended for grant (clean copy)
Sep 21, 2018
Text intended for grant (version for approval)
Jul 31, 2018
Examination started
May 16, 2018
Notification regarding date of start of examination with possibility to withdraw
Dec 22, 2017
Communication of the registration of a transfer or change of name and/or address
Aug 4, 2017
Communication of amended entries concerning the representative
Jul 31, 2017
Submission concerning change of applicant's representative
Jul 25, 2017
(Electronic) Receipt
Jul 25, 2017
Annexes in respect of a client data request
Jul 25, 2017
Letter accompanying subsequently filed items
Jul 25, 2017
Submission concerning a transfer of rights (applicant)
Jun 28, 2016
Submission concerning representation
Jan 25, 2016
(Electronic) Receipt
Jan 25, 2016
Amended claims filed after receipt of (European) search report
Jan 25, 2016
Amended claims with annotations
Jan 25, 2016
Amendments received before examination
Jan 25, 2016
Citation for the examination procedure
Jan 25, 2016
Letter accompanying subsequently filed items
Jan 11, 2016
Notice drawing attention to the payment of the renewal fee and additional fee
Dec 2, 2015
Confirmation of revocation of automatic debit order
Nov 27, 2015
Letter relating to the automatic debiting procedure
Sep 2, 2015
Notification on forthcoming publication of bibliographic data
Jul 23, 2015
Communication concerning correction of deficiencies in written opinion/amendment of application/payment of claims fee
Jul 13, 2015
Communication to designated inventor
Jul 13, 2015
Communication to designated inventor
Jul 13, 2015
Communication to designated inventor
Jul 13, 2015
Communication to designated inventor
Jul 13, 2015
Communication to designated inventor
Jun 8, 2015
Copy of the international preliminary report on patentability
May 26, 2015
(Electronic) Receipt
May 26, 2015
Request for entry into the European phase
Apr 24, 2015
Information on entry into European phase
Jul 7, 2014
Priority document (electronically transmitted)
Jun 19, 2014
Copy of the international search report
Jun 19, 2014
Published international application - A1
Jun 4, 2014
Written opinion of the ISA, boxes No. I to VIII
Jun 4, 2014
Written opinion of the ISA, cover sheet
Jun 4, 2014
Written opinion of the ISA, supplemental box
Apr 25, 2014
Abstract
Apr 25, 2014
Claims
Apr 25, 2014
Description
Apr 25, 2014
Drawings

EP2922532

ALLERGAN PHARMACEUTICALS

Application Number: EP13849986A
Filing Date: Nov 19, 2013
Status: Revoked; Oct 23, 2020
Publication Date: Mar 6, 2019
External Links: Slate, Register , Google Patents

IP Verse

5-Aminosalicylic Acid Capsule Formulation

Patent Summary

Patent Family

Patent Oppositions

Dossier Documents

EP2922532